FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00656 FOSUN INTL

Not Yet Opened 12-22 16:08:10

4.570

-0.070

-1.51%

High4.670	Low4.560	Vol4.27M
Open4.640	D1 Closing4.640	Amplitude2.37%
Mkt Cap37.32B	Tradable Cap37.32B	Total Shares8.17B
T/O19.57M	T/O Rate0.05%	Tradable Shares8.17B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00656","market":"HK","secType":"STK","nameCN":"FOSUN INTL","latestPrice":4.57,"timestamp":1766390890002,"preClose":4.64,"halted":0,"volume":4267951,"delay":0,"floatShares":8167000000,"shares":8167000000,"eps":-0.591519165003073,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"12-22 16:08:10","open":4.64,"high":4.67,"low":4.56,"amount":19569537,"amplitude":0.023707,"askPrice":4.57,"askSize":318000,"bidPrice":4.56,"bidSize":327500,"shortable":3,"etf":0,"ttmEps":-0.6000586056388432,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":0,"adr":0,"listingDate":1184515200000,"exchange":"SEHK","adjPreClose":4.64,"dividendRate":0.004376,"openAndCloseTimeList":[[1766367000000,1766376000000],[1766379600000,1766390400000]],"volumeRatio":1.020280385245129,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00656","defaultTab":"news","newsList":[{"id":"2593171745","title":"Fosun International Receives Outstanding ESG Award at TVB ESG Awards 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593171745?lang=en_us&edition=fundamental","pubTime":"2025-12-22 09:00","pubTimestamp":1766365215,"startTime":"0","endTime":"0","summary":"Fosun International Limited announced that it received the \"Outstanding ESG Award\" at the TVB ESG Awards 2025 Presentation Ceremony, along with awards for \"Best in ESG Practices\" and \"Best in ESG Report.\" The event was held at the Hong Kong Convention and Exhibition Center on December 19, 2025. The awards recognize organizations for their performance in environmental, social, and governance  practices and reporting. Fosun International was among several organizations, including government bodies and public utilities, to receive the highest accolade. The company stated it will continue to focus on its core businesses, innovation, and global sustainability trends.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL1dLtJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2592527431","title":"FDA Approves Shanghai Henlius Biotech's IND Application for Nivolumab Biosimilar HLX18 Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592527431","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592527431?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:03","pubTimestamp":1766135022,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its investigational new drug application for a phase 1 clinical trial of HLX18, a nivolumab biosimilar , has been approved by the United States Food and Drug Administration . HLX18 is independently developed by Henlius for the treatment of multiple solid tumors. The company plans to initiate the clinical trial in the United States when conditions permit. No other organizations are mentioned as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 19, 2025, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL4mw4c6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1230","BK1161","00656","02696"],"gpt_icon":0},{"id":"2592917636","title":"PAREF Enters Exclusive Talks to Sell SOLIA Paref","url":"https://stock-news.laohu8.com/highlight/detail?id=2592917636","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592917636?lang=en_us&edition=fundamental","pubTime":"2025-12-18 02:15","pubTimestamp":1765995335,"startTime":"0","endTime":"0","summary":"PAREF Group has entered into exclusive negotiations to sell its property management subsidiary, SOLIA Paref. Launched in June 2024, SOLIA Paref manages approximately 950 leases across 350 assets in France, covering sectors such as retail, offices, logistics, senior housing, and hospitality. The divestment is part of PAREF’s strategy to focus on its core activities of fund management, investment, and asset management, aiming to strengthen long-term performance and profitability. The group has initiated the information and consultation process with its Works Council regarding this project.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAREF SCA - Paris Realty Fund published the original content used to generate this news brief on Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2mS3B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"1174871463","title":"Guo Guangchang's 1.4 Billion Bet on Domestic Alzheimer's \"Miracle Drug\" Draws Regulatory Scrutiny","url":"https://stock-news.laohu8.com/highlight/detail?id=1174871463","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174871463?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:50","pubTimestamp":1765889445,"startTime":"0","endTime":"0","summary":"Amid production halts and regulatory setbacks for its core product, Fosun Pharma's planned controlling stake acquisition of Green Valley Pharma has sparked intense market attention. Even before the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2591862118","title":"BUZZ-Pfizer shares up ahead of co analyst and investor call Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2591862118","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591862118?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:52","pubTimestamp":1765831962,"startTime":"0","endTime":"0","summary":"** Shares of Pfizer PFE.N are up 2.9% on Mon ahead of the co's analyst and investor. ** Analysts expecting Q1 2026 EPS of 77 cents and FY 2026 EPS of $3.05, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999002224.SGD","BK0239","BK1230","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","BK4007","BK4592","IE00BBT3K403.USD","LU0306806265.USD","LU1894683348.USD","600196","BK4599","LU1883839398.USD","BK0012","LU1894683264.USD","IE0002270589.USD","SG9999002232.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","SG9999013999.USD","LU0321505439.SGD","LU0058720904.USD","PFE","SG9999001176.USD","LU0321505868.SGD","LU0289739699.SGD","LU0122379950.USD","LU0170899867.USD","LU0225771236.USD","LU1066051498.USD","SG9999001176.SGD","SG9999011175.SGD","LU0225284248.USD","LU0456855351.SGD","LU0234572021.USD","BK4568","BK0028","SG9999003800.SGD","BK4588","BK4534","BK0188","BK0060","BK4581","LU1066053197.SGD","BK0196","00656","BK0187","BK0096"],"gpt_icon":1},{"id":"2591640932","title":"BRIEF-Fosun International Says Fosun Pharma Industrial To Buy Aggregate 8.6667% Stake In Green Valley (Shanghai) Pharmaceutical Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640932","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591640932?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:25","pubTimestamp":1765812322,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun International Says Fosun Pharma Industrial To Buy Aggregate 8.6667% Stake In Green Valley (Shanghai) Pharmaceutical TechnologyDec 15 (Reuters) - Fosun International Ltd 0656.HK:FOSUN PHARM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2591422006","title":"Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2591422006","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591422006?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:38","pubTimestamp":1765809515,"startTime":"0","endTime":"0","summary":"Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle , with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL736gGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","BK0060","BK0188","BK0239","BK0183","BK0012","BK0175","BK0028","BK0196","600196","00656","BK0096","BK0187"],"gpt_icon":0},{"id":"2591642487","title":"Fosun International - Acquisition Total Consideration Is RMB143 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591642487?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:37","pubTimestamp":1765809448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0UV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2591424826","title":"Fosun International - Fosun Pharma Industrial to Acquire Aggregate 8.6667% Stake in Green Valley (Shanghai) Pharmaceutical Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2591424826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591424826?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:37","pubTimestamp":1765809448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1230","00656"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","IE0002141913.USD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","SRRK","SG9999015986.USD","LU2106854487.HKD","03933","03692","LU0345777147.USD","AZN.UK","SG9999013999.USD","ALT","BK4566","LLY","600196","SG9999014906.USD","LU0306806265.USD","IE00BJJMRX11.SGD","BK0187","LU1061106388.HKD","MTSR","LU0106261372.USD","AMGN","MRK","LU0130517989.USD","SG9999002224.SGD","LU0256863902.USD","LU0211328371.USD","VKTX","LU1323610961.USD","LU0964806797.USD","LU1003077747.HKD","LU1035775433.USD","IE00BJLML261.HKD","00656","LU1720051017.SGD","BK0188","GPCR","SGXZ99366536.SGD","03165","LU0823434583.USD","OPK","LU1989772840.SGD","BK0028","IE00B4JS1V06.HKD","LU0499090636.EUR","LU1989771016.USD","02105"],"gpt_icon":1},{"id":"2590503933","title":"Shanghai Fosun Pharmaceutical Subsidiary Wins Approval for Ketoprofen Patch Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503933","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503933?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:36","pubTimestamp":1765539382,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Subsidiary Zhaohui Pharma Receives Approval for Ketoprofen Patch Phase III Clinical Trial. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLc6cwnx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK1230","BK0060","BK0239","BK0012","BK0188","600196","BK0028","BK0196","BK0096","00656","BK0183","BK0175"],"gpt_icon":0},{"id":"2590719945","title":"Henlius Biotech's Serplulimab NDA for Gastric Cancer Combo Granted Priority Review by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590719945","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590719945?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:48","pubTimestamp":1765529285,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its New Drug Application  for HANSIZHUANG  in combination with chemotherapy for neo-/adjuvant treatment of gastric cancer has been accepted by the National Medical Products Administration  of China and has been granted priority review. This regulatory milestone follows the achievement of the primary endpoint in a Phase 3 clinical trial in mainland China. No other organizations were mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1YbQhN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","HK0000165453.HKD","02696","BK1161","BK1230"],"gpt_icon":0},{"id":"2590311384","title":"Shanghai Henlius Biotech Secures NMPA Approval for Phase 2/3 Trials of HLX22 and HLX87 in HER2-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311384","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311384?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271717,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the National Medical Products Administration has approved applications for Phase 2/3 clinical trials of HLX22  in combination with HLX87  for the first-line treatment and neoadjuvant treatment of HER2-positive breast cancer. As of the announcement date, no similar combination has been approved for marketing globally. The approval marks a significant step forward in the company's oncology pipeline, but Henlius cautioned that successful development and commercialization of HLX22 and HLX87 cannot be guaranteed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service opera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1L7tPm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","02696","HK0000165453.HKD","BK1161","00656"],"gpt_icon":0},{"id":"2589355863","title":"Sisram Medical Announces Board and CEO Changes Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355863","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355863?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:24","pubTimestamp":1765200246,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd. has announced changes to its management and board, effective January 1, 2026. Yi Liu, Lior Moshe Dayan, and Jiahong Li serve as executive directors, while Yifang Wu and Rongli Feng are non-executive directors. The board also includes Heung Sang Addy Fong, Chi Fung Leo Chan, Jenny Chen, and Kai Yu Kenneth Liu as independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6z3QLr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","00656","BK1230","BK1593","01696","BK1585"],"gpt_icon":0},{"id":"2589384401","title":"BNP Paribas increases stake in Belgium's largest insurer in $3.5 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384401","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589384401?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:44","pubTimestamp":1765176254,"startTime":"0","endTime":"0","summary":"UPDATE 2-BNP Paribas increases stake in Belgium's largest insurer in $3.5 billion dealBNP Paribas to increase stake in Ageas to 22.5%Ageas gains full control of AG InsuranceDeal includes renewed partn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL8N3XE06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230"],"gpt_icon":0},{"id":"2589037871","title":"Shanghai Henlius Biotech's FUTUONING Added to China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589037871","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589037871?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:25","pubTimestamp":1765103102,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its product FUTUONING  has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance  for 2025 in mainland China. The approval covers the use of FUTUONING in combination with Fulvestrant for the treatment of adult patients with hormone receptor positive and HER2 negative recurrent or metastatic breast cancer who have experienced disease progression after prior endocrine therapy. The updated NRDL will take effect from January 1, 2026, increasing patient access to FUTUONING and supporting the company's marketing and sales efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL2mHPQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","00656","BK1230","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588216500","title":"Does Fosun International’s Streamlining Strategy Make Its Low Valuation Look More Appealing in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588216500","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588216500?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:23","pubTimestamp":1764771816,"startTime":"0","endTime":"0","summary":"Wondering if Fosun International at HK$4.97 is quietly turning into a value opportunity, or just another value trap in Hong Kong stocks.\nThe share price is up 0.6% over the last week, 1.2% over the past month, and 12.7% year to date, yet anyone who has held for 3 or 5 years is still looking at -16.2% and -51.5% respectively.\nRecent headlines have focused on Fosun International streamlining its portfolio and deleveraging its balance sheet, as the group continues to refocus on core businesses...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice2-main-header/1585186874993"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/does-fosun-internationals-streamlining-strategy-make-its-low","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-656/fosun-international-shares/news/does-fosun-internationals-streamlining-strategy-make-its-low","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00656","DCF","BK1230"],"gpt_icon":0},{"id":"2588044653","title":"Shanghai Henlius Biotech Inc. Announces Date for 2025 Fourth Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044653?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:06","pubTimestamp":1764770763,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has scheduled its 2025 Fourth Extraordinary General Meeting for 31 December 2025. The meeting will be held at the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, PRC. Shareholders will have the opportunity to vote on the resolutions as set out in the meeting notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL92cp7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK1230","HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2588041759","title":"Shareholders to Vote on Renewal of Sinopharm Distribution Collaboration at Shanghai Henlius Biotech Inc. EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588041759","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588041759?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:57","pubTimestamp":1764770263,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. will hold an Extraordinary General Meeting on December 31, 2025, where shareholders will vote on the renewal of the Sinopharm distribution collaboration, a continuing connected transaction. The Independent Board Committee has issued a recommendation regarding the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1C0xBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1230","BK1161","02696","00656"],"gpt_icon":0},{"id":"2588204114","title":"Shanghai Henlius Biotech Partners with Avanc Pharma for Fovinaciclib Citrate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588204114","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588204114?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:48","pubTimestamp":1764769683,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. has entered into collaboration agreements with Avanc Pharma for the commercialisation of fovinaciclib citrate capsules. Under the terms of the agreements signed on December 3, 2025, Avanc Pharma will grant Henlius an exclusive license to commercialise the licensed product in designated areas and channels within China. The partnership follows a prior memorandum of cooperation and sets out arrangements for supply and commercialisation services, with Henlius handling distribution in regions where Avanc Pharma is permitted to sell the product under local policies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL4h08B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000165453.HKD","02696","00656","BK1230"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosun.com","stockEarnings":[{"period":"1week","weight":-0.0439},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.1506},{"period":"6month","weight":-0.0108},{"period":"1year","weight":0.0088},{"period":"ytd","weight":0.0111}],"compareEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0231},{"period":"3month","weight":-0.0137},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3084},{"period":"ytd","weight":0.2862}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Fosun International Ltd is a company principally engaged in the operation and investments in global consumer business. The Company operates its business through five segments. The Happiness segment engages in the operation and investments in tourism and leisure, fashion consumer and lifestyle industries. The Health segment engages in the research and development, manufacture, sale and trading of pharmaceutical and health products and providing medical services and health management. The Insurance segment mainly engages in the operation of and investment in the insurance businesses. The Asset Management segment comprises principally the operation and investment of asset management, market investments, and investments in other companies of the Group. The Intelligent Manufacturing segment comprises principally the operation of and investment in the intelligent manufacturing and iron, steel, new functional materials and ore production.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.007963},{"month":2,"riseRate":0.5,"avgChangeRate":0.01453},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000408},{"month":4,"riseRate":0.555556,"avgChangeRate":0.034582},{"month":5,"riseRate":0.555556,"avgChangeRate":0.040571},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.012529},{"month":7,"riseRate":0.388889,"avgChangeRate":0.000713},{"month":8,"riseRate":0.105263,"avgChangeRate":-0.050815},{"month":9,"riseRate":0.578947,"avgChangeRate":-0.012339},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.019588},{"month":11,"riseRate":0.473684,"avgChangeRate":0.019122},{"month":12,"riseRate":0.526316,"avgChangeRate":0.022641}],"exchange":"SEHK","name":"FOSUN INTL","nameEN":"FOSUN INTL"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FOSUN INTL,00656,FOSUN INTL股票,FOSUN INTL股票老虎,FOSUN INTL股票老虎国际,FOSUN INTL行情,FOSUN INTL股票行情,FOSUN INTL股价,FOSUN INTL股市,FOSUN INTL股票价格,FOSUN INTL股票交易,FOSUN INTL股票购买,FOSUN INTL股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FOSUN INTL(00656),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FOSUN INTL(00656) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}